Report of Foreign Issuer (6-k)
September 21 2016 - 4:51PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
Report
of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under
the Securities Exchange Act of 1934
For
the Month of September 2016
001-36203
(Commission
File Number)
CAN-FITE
BIOPHARMA LTD.
(Exact
name of Registrant as specified in its charter)
10
Bareket Street
KiryatMatalon,
P.O. Box 7537
Petach-Tikva
4951778, Israel
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover
Form 20-F
or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T
Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T
Rule 101(b)(7): ____
This
Report on Form 6-K (including exhibits thereto) is hereby incorporated by reference into the registrant's Registration Statements
on Form F-3 (File Nos. 333-195124, 333-199033, 333-204795 and 333-209037), to be a part thereof from the date on which this report
is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
On
September 21, 2016, Can-Fite BioPharma Ltd. (the “Can-Fite”), as parent and majority shareholder of OphthaliX, Inc.
(“OphthaliX”) consented in writing to, among other things, the voluntary dissolution and liquidation of OphthaliX
pursuant to a Plan of Dissolution. The Plan of Dissolution, which will result in the complete dissolution and liquidation of OphthaliX,
is expected to go into effect 20 days after the date an Information Statement is first given to all stockholders of OphthaliX
who did not execute the written consent.
In
connection with the Plan of Dissolution, Can-Fite plans to enter into a share purchase agreement providing for the sale to Can-Fite
of all the ordinary shares of OphthaliX’s wholly owned subsidiary, Eyefite Ltd., which at the time will be a holder of 446,827
ordinary shares of Can-Fite, is the registered owner of certain patents, and licensee of a license agreement granted by Can-Fite
to Eyefite (the “License Agreement”). As a result of the sale, Eyefite will become a wholly-owned subsidiary of Can-Fite.
In exchange for the sale, Can-Fite will waive and cancel all indebtedness owed by OphthaliX and Eyefite to Can-Fite, including
approximately $4.5 million of deferred payments owed by OphthaliX and Eyefite to Can-Fite and as part of the purchase of Eyefite,
Can-Fite will assume certain accrued milestone payments in the amount of $175,000 under the License Agreement.
Following
the sale of Eye-Fite, it is expected that (i) Eye-Fite may, in its sole discretion, sell or otherwise transfer the 446,827 ordinary
shares of Can-Fite, (ii) Eye-Fite and Can-Fite will mutually terminate the License Agreement and a related services agreement,
and (iii) Eye-Fite will abandon certain patents and patent applications that it is the registered owner of.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
Can-FiteBioPharma
Ltd.
|
|
|
|
Date:
September 21, 2016
|
By:
|
/s/
Pnina Fishman
|
|
|
Pnina
Fishman
|
|
|
Chief
Executive Officer
|
3
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Aug 2024 to Sep 2024
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Sep 2023 to Sep 2024